Physician profile
Thomas Eugene Edwards
NPI 1558599159
$2,951.03
in general payments reported to CMS, 2019-2025
35 companies · $742 in 2025
The $742 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.15 · 2020: $24.89 · 2021: $277 · 2022: $419 · 2023: $730 · 2024: $735 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,206.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $375.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $336.92 | 2019-2025 | |
| Dexcom, INC. | $336.22 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $195.85 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Corium, LLC | $166.72 | 2021-2023 | Azstarys |
| Almatica Pharma LLC | $131.37 | 2021-2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Astrazeneca Pharmaceuticals LP | $122.14 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $119.37 | 2022-2025 | Viberzi, Linzess |
| Lilly USA, LLC | $100.57 | 2022-2025 | Zepbound, Mounjaro, Kisunla |
| Seqirus USA INC | $92.42 | 2022-2025 | Flucelvax, Fluad |
| Otsuka America Pharmaceutical, INC. | $81.96 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $75.93 | 2021-2024 | Veozah, Myrbetriq |
| Amgen INC. | $74.07 | 2023-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.26 | 2022-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $70.73 | 2024-2025 | Auvelity |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $68.73 | 2023-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $54.79 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.91 | 2021-2022 | |
| Exact Sciences Corporation | $38.38 | 2024-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $37.57 | 2023-2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.14 | 2021 | |
| Janssen Pharmaceuticals, INC | $33.95 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.43 | 2022 | |
| Radius Health, INC. | $32.09 | 2024 | Tymlos |
| Grifols USA, LLC | $30.63 | 2025 | Prolastin-C Liquid |
| Hologic Sales and Service, LLC | $27.67 | 2023-2024 | Aptima |
| Novartis Pharmaceuticals Corporation | $23.98 | 2022 | |
| Linus Health, INC. | $19.74 | 2023 | |
| Supernus Pharmaceuticals, INC. | $19.43 | 2021 | |
| Corcept Therapeutics | $18.97 | 2024 | Korlym |
| Abbott Laboratories | $18.58 | 2021 | |
| Inari Medical, INC. | $18.54 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $17.85 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $16.04 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.